Retatrutide in North Dakota: Market Status and Research Records
At a glance
- Review question / What do federal sources and ClinicalTrials.gov records establish about retatrutide in North Dakota?
- Best evidence / federal status and trial-registry records
- Evidence snapshot / 2026-08-09
- Commercial status / no FDA-approved product or ordinary retail supply
- HealthRX role / independent educational review; no retatrutide product or treatment offer
Direct answer
Retatrutide is not commercially available in the state. There is no FDA-approved retatrutide product, approved label, ordinary wholesale listing, retail pharmacy supply, or insurer benefit from which a legitimate public price in North Dakota could be derived. The same registry snapshot listed 4 study records with a North Dakota location, but research-site records and sponsor study costs are not retail prices.
The wording here is deliberately evidence-specific. “A study exists,” “a registry lists a site,” and “a paper reports an endpoint” are different statements from “a product is approved,” “a treatment works,” or “a person should use it.” This page makes only the first type of statement and links the controlling source.
Evidence map for market status in North Dakota
| Primary source | What the record documents | What the record cannot establish alone |
|---|---|---|
| FDA status statement for unapproved GLP-1 drugs | Documents that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| FDA warning letter addressing compounded retatrutide | Explains why retatrutide products described as compounded did not qualify for the federal compounding exemptions discussed in the letter. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| ClinicalTrials.gov pre-approval expanded-access record NCT07629401 | A registry entry for eligibility-limited pre-approval expanded access. It is not commercial approval, retail availability, ordinary prescribing, or a HealthRX service. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| 21 CFR 312.7, Promotion of investigational drugs | Separates scientific exchange from promotional representations of an investigational drug as safe or effective. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
How HealthRX evaluated this question
A market-status review starts with the regulatory product record. Without FDA approval, approved labeling, an identified commercial product, and a lawful distribution channel, retail-price and insurance-benefit claims have no verified object. Research budgets, site payments, purported API prices, and seller quotes answer different questions and are excluded.
For this page, HealthRX asked: (1) Is market status in North Dakota named in the protocol or publication? (2) Was it a prespecified endpoint, eligibility factor, subgroup, or only background context? (3) Is the record complete, current, and peer reviewed? (4) Does an FDA action or approved label exist? That sequence prevents a research observation from being rewritten as a product claim.
Evidence checks specific to this record
Subgroup stability
A subgroup result needs adequate representation, a prespecified interaction test, transparent multiplicity handling, and consistency across relevant analyses. Merely listing a demographic or clinical subgroup does not establish a subgroup-specific conclusion about market status in North Dakota.
Clinical meaning
Statistical reporting and clinical interpretation are separate steps. A study should define the endpoint and uncertainty around it, while an approved label or guideline supplies reviewed public-use context. For market status in North Dakota, do not substitute a numerical result for regulatory or clinical guidance.
Question-to-source fit
Use the source that can actually answer the question. FDA records control regulatory status, registries document study plans, protocols define methods, and publications report analyses. For market status in North Dakota, a lower-level source should not be used to make a higher-level claim.
Terminology discipline
Keep 'investigational,' 'registered,' 'completed,' 'published,' 'expanded access,' and 'FDA-approved' distinct. For market status in North Dakota, these terms describe different stages or pathways and should never be collapsed into the idea that a commercial treatment is available.
Missing-data handling
Check participant flow, discontinuations, missing measurements, and the estimand used for analysis. For market status in North Dakota, a result based only on completers may answer a different question from an analysis that accounts for everyone randomized.
What remains unresolved
Federal approval and compounding status do not change by state. A quoted amount from a seller, clinic, API distributor, or purported compounder is not evidence of a lawful retatrutide price or product in North Dakota.
The source hierarchy also matters. An FDA action controls approval status. ClinicalTrials.gov controls the public registry record. A peer-reviewed report can describe study methods and observations. A press release, seller page, social post, search result, or anecdote cannot replace those sources.
What evidence could change the answer
A legitimate public price question could arise only after FDA approval, approved labeling, an identified commercial product, and verifiable manufacturer or payer records. None of those elements can be inferred from a trial site.
Any new result should be read with its protocol and statistical analysis plan. Important checks include enrollment, prespecified outcomes, follow-up duration, missing-data handling, multiplicity, participant flow, sponsor involvement, and whether the finding has undergone peer review and regulatory review.
Current federal and commercial status
Retatrutide remains investigational. No retatrutide product is FDA-approved for any indication or available through ordinary commercial prescription or retail sale. FDA states that retatrutide cannot be used in compounding under federal law. HealthRX does not offer it. FDA's current statement says retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. A ClinicalTrials.gov study or eligibility-limited expanded-access record is not commercial approval, ordinary prescribing, retail availability, or evidence that HealthRX offers the investigational substance.
Federal regulation distinguishes scientific exchange from promotion: it does not restrict full exchange of scientific information, but it does restrict representing an investigational drug as safe or effective in a promotional context and precludes commercialization before approval.
Source selection and review method
HealthRX reviewed primary or primary-index sources current to 2026-08-09: FDA status statement for unapproved GLP-1 drugs; FDA warning letter addressing compounded retatrutide; ClinicalTrials.gov pre-approval expanded-access record NCT07629401; 21 CFR 312.7, Promotion of investigational drugs. Sources were selected because they control regulatory status, register a study, or index a peer-reviewed clinical report. The review reports study design and evidence limits without reproducing promotional outcome claims or converting protocols into patient instructions.
Frequently asked questions
Is there a legitimate retail price for retatrutide in this state?
No. There is no FDA-approved commercial retatrutide product or ordinary retail supply from which a legitimate public price can be established.
Do research-site or seller amounts establish a market price?
No. Study costs, site payments, API listings, and seller quotes are not verified prices for an FDA-approved product and should not be presented as such.
What records would make a future price review possible?
An FDA approval action, approved labeling, an identified commercial product, and verifiable manufacturer, wholesaler, pharmacy, or payer documentation would be needed.
References
- U.S. Food and Drug Administration. FDA status statement for unapproved GLP-1 drugs. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- U.S. Food and Drug Administration. FDA warning letter addressing compounded retatrutide. 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/asn-labs-09092025
- ClinicalTrials.gov. Pre-approval expanded-access registry record. 2026. https://clinicaltrials.gov/study/NCT07629401
- Electronic Code of Federal Regulations. 21 CFR 312.7, Promotion of investigational drugs. 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.7